Crizotinib changes the metabolic pattern and inhibits ATP production in A549 non-small cell lung cancer cells

Crizotinib, an inhibitor of the hepatocyte growth factor receptor oncogene, has been studied extensively regarding its antitumor and clinically beneficial effects in non-small cell lung cancer (NSCLC). However, crizotinib's effects on cancer cell energy metabolism, which is linked with tumor pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Sa, Zhou, Hong-Bin, Chen, Ying, Li, Kai-Qiang, Jiang, Shan-Shan, Hao, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709560/
https://www.ncbi.nlm.nih.gov/pubmed/33281972
http://dx.doi.org/10.3892/ol.2020.12323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709560/
https://www.ncbi.nlm.nih.gov/pubmed/33281972
http://dx.doi.org/10.3892/ol.2020.12323

Ejemplares similares